Vanda Pharmaceuticals Files 8-K

TL;DR

Vanda Pharma filed an 8-K on May 7th, likely for financial updates.

AI Summary

Vanda Pharmaceuticals Inc. filed an 8-K on May 7, 2024, to report other events and financial statements. The filing does not detail specific transactions or financial results but serves as a notification of these items to the SEC.

Why It Matters

This 8-K filing indicates that Vanda Pharmaceuticals is providing updates to the SEC regarding its financial statements and other corporate events.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• Vanda Pharmaceuticals Inc. (company) — Registrant
• 20240507 (date) — Date of Report
• 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 (address) — Principal executive offices
• (202) 734-3400 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma

Filing Documents

• d810702d8k.htm (8-K) — 27KB
• d810702dex991.htm (EX-99.1) — 4KB
• 0001193125-24-133252.txt ( ) — 188KB
• vnda-20240507.xsd (EX-101.SCH) — 4KB
• vnda-20240507_def.xml (EX-101.DEF) — 13KB
• vnda-20240507_lab.xml (EX-101.LAB) — 22KB
• vnda-20240507_pre.xml (EX-101.PRE) — 14KB
• d810702d8k_htm.xml (XML) — 6KB

Forward Looking Statements

Forward Looking Statements Various statements this document are "forward-looking statements" under the securities laws. The words "believe," "will," "intend," and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this document. Although Vanda believes any such statements are based on reasonable assumptions, actual outcomes may differ materially. Any such statements are made in reliance on the "safe harbor" protections provided under the Private Securities Reform Act of 1995. Forward-looking statements in this document should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available at www.sec.gov. All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this document is provided only as of the date hereof, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Item9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated May 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL d

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 7, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR